Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)
14.86
+0.05 (0.34%)
Feb 4, 2026, 3:04 PM CST
SHE:002365 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 234.84 | 320.41 | 326.17 | 274.72 | 93.51 | 114.2 |
Trading Asset Securities | 687.31 | 600.16 | 630.1 | 557.5 | 454.02 | 634.1 |
Cash & Short-Term Investments | 922.15 | 920.57 | 956.27 | 832.22 | 547.53 | 748.3 |
Cash Growth | 4.77% | -3.73% | 14.91% | 52.00% | -26.83% | 49.05% |
Accounts Receivable | 134.82 | 161.79 | 171.53 | 187.23 | 332.27 | 162.91 |
Other Receivables | 9.34 | 6.14 | 6.33 | 8.12 | 11.63 | 10.57 |
Receivables | 144.16 | 167.93 | 177.86 | 195.35 | 343.9 | 173.48 |
Inventory | 78.41 | 93.5 | 69.9 | 149.6 | 145.78 | 81.67 |
Other Current Assets | 22.93 | 16.66 | 9.57 | 18.18 | 28.69 | 24.11 |
Total Current Assets | 1,168 | 1,199 | 1,214 | 1,195 | 1,066 | 1,028 |
Property, Plant & Equipment | 909.13 | 948.07 | 953.61 | 1,022 | 988.96 | 989.6 |
Long-Term Investments | 77.89 | 74.55 | 68.3 | 81.37 | 115.23 | 35.27 |
Goodwill | - | - | 0.52 | 8.77 | 8.77 | 8.77 |
Other Intangible Assets | 77.73 | 79.56 | 82.39 | 84.49 | 87.93 | 89.82 |
Long-Term Deferred Tax Assets | 8.84 | 5.84 | 11.26 | 9.73 | 9.94 | 9.37 |
Other Long-Term Assets | 21.19 | 1.93 | 17.46 | 22.03 | 9.21 | 3.35 |
Total Assets | 2,262 | 2,309 | 2,347 | 2,424 | 2,286 | 2,164 |
Accounts Payable | 121.26 | 124.02 | 160.65 | 162.77 | 114.91 | 97.58 |
Accrued Expenses | 31.93 | 41.07 | 40.04 | 47.5 | 47 | 40.67 |
Short-Term Debt | 28.37 | 39.53 | 10.01 | 40.01 | 20.38 | 122.35 |
Current Income Taxes Payable | 7.27 | 7.06 | 7.84 | 0.61 | 2.37 | 2.25 |
Current Unearned Revenue | 22.98 | 19.28 | 15.59 | 11.77 | 21.53 | 19.82 |
Other Current Liabilities | 20.61 | 17.38 | 23.12 | 22.46 | 87.18 | 27.57 |
Total Current Liabilities | 232.43 | 248.34 | 257.26 | 285.13 | 293.37 | 310.24 |
Long-Term Unearned Revenue | 6.07 | 7.46 | 8.5 | 11.31 | 13.05 | 14.2 |
Long-Term Deferred Tax Liabilities | 8.69 | 10.75 | 33.09 | 24.74 | 22.53 | 25.49 |
Total Liabilities | 247.2 | 266.55 | 298.85 | 321.17 | 328.95 | 349.92 |
Common Stock | 294.68 | 294.68 | 294.68 | 294.68 | 294.68 | 294.68 |
Additional Paid-In Capital | 714.5 | 714.44 | 712.92 | 712.78 | 712.23 | 691.12 |
Retained Earnings | 982.49 | 985.91 | 953.42 | 995.2 | 854.85 | 772.87 |
Treasury Stock | -40.48 | -24.18 | - | - | - | -3.79 |
Comprehensive Income & Other | 25.23 | 22.94 | 22.89 | 14.71 | 4.16 | 0.84 |
Total Common Equity | 1,976 | 1,994 | 1,984 | 2,017 | 1,866 | 1,756 |
Minority Interest | 38.8 | 48.28 | 64.38 | 85.63 | 91.06 | 58.1 |
Shareholders' Equity | 2,015 | 2,042 | 2,048 | 2,103 | 1,957 | 1,814 |
Total Liabilities & Equity | 2,262 | 2,309 | 2,347 | 2,424 | 2,286 | 2,164 |
Total Debt | 28.37 | 39.53 | 10.01 | 40.01 | 20.38 | 122.35 |
Net Cash (Debt) | 893.78 | 881.04 | 946.26 | 792.2 | 527.15 | 625.95 |
Net Cash Growth | 3.91% | -6.89% | 19.45% | 50.28% | -15.78% | 25.43% |
Net Cash Per Share | 3.07 | 2.99 | 3.21 | 2.69 | 1.84 | 2.17 |
Filing Date Shares Outstanding | 289.15 | 289.15 | 294.68 | 294.68 | 294.68 | 294.28 |
Total Common Shares Outstanding | 289.15 | 291.24 | 294.68 | 294.68 | 294.68 | 294.28 |
Working Capital | 935.22 | 950.32 | 956.34 | 910.22 | 772.52 | 717.31 |
Book Value Per Share | 6.84 | 6.85 | 6.73 | 6.85 | 6.33 | 5.97 |
Tangible Book Value | 1,899 | 1,914 | 1,901 | 1,924 | 1,769 | 1,657 |
Tangible Book Value Per Share | 6.57 | 6.57 | 6.45 | 6.53 | 6.00 | 5.63 |
Buildings | - | 581.93 | 573.53 | 546.87 | 547.89 | 526.88 |
Machinery | - | 1,306 | 1,268 | 1,210 | 1,083 | 1,039 |
Construction In Progress | - | 66.41 | 26.12 | 51.55 | 43.07 | 4.47 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.